These findings imply that MYC is a novel target for pharmacological intervention, not only in fibroproliferative expansion of smooth muscle in hollow organs, but also in cancers in which PDGFR-dependent signaling and/or MYC activation are drivers of tumor progression. The gene discussed is PDGFRB; the disease is cancer.